Cesare Sarrecchia

Summary

Affiliation: University of Rome Tor Vergata
Country: Italy

Publications

  1. ncbi request reprint [Interstitial pulmonary fibrosis in chronic HCV hepatitis treated with interferon]
    C Sarrecchia
    Dipartimento di Sanita Pubblica, Universita Tor Vergata, Roma
    Recenti Prog Med 92:336-9. 2001
  2. ncbi request reprint HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb
    Cesare Sarrecchia
    Universita di Roma Tor Vergata, Dipartimento di Sanita Pubblica, Rome, Italy
    J Infect Chemother 11:189-91. 2005
  3. doi request reprint Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance
    C Sarrecchia
    Department of Public Health, University of Rome Tor Vergata, Rome, Italy
    Infection 39:367-70. 2011
  4. doi request reprint Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy
    Laura Ceccarelli
    Infectious Disease Unit, Tor Vergata University Hospital, Rome, Italy
    J Infect 65:180-3. 2012
  5. doi request reprint Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen
    Valeria Cento
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 00100 Rome, Italy
    J Infect 67:303-12. 2013
  6. pmc HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors
    Valeria Cento
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata, Rome, Italy
    PLoS ONE 7:e39652. 2012

Collaborators

Detail Information

Publications6

  1. ncbi request reprint [Interstitial pulmonary fibrosis in chronic HCV hepatitis treated with interferon]
    C Sarrecchia
    Dipartimento di Sanita Pubblica, Universita Tor Vergata, Roma
    Recenti Prog Med 92:336-9. 2001
    ..The correlation among interstitial pulmonary fibrosis, HCV infection and interferon treatment is discussed; however in the described case, the pulmonary pathology was correlated to interferon treatment...
  2. ncbi request reprint HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb
    Cesare Sarrecchia
    Universita di Roma Tor Vergata, Dipartimento di Sanita Pubblica, Rome, Italy
    J Infect Chemother 11:189-91. 2005
    ....
  3. doi request reprint Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance
    C Sarrecchia
    Department of Public Health, University of Rome Tor Vergata, Rome, Italy
    Infection 39:367-70. 2011
    ....
  4. doi request reprint Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy
    Laura Ceccarelli
    Infectious Disease Unit, Tor Vergata University Hospital, Rome, Italy
    J Infect 65:180-3. 2012
    ..Furthermore, it is of outstanding importance to identify alternative markers (e.g. cccDNA, HBV core related antigen, etc.), that could be predictive of HBV reactivation...
  5. doi request reprint Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen
    Valeria Cento
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 00100 Rome, Italy
    J Infect 67:303-12. 2013
    ..Furthermore, due to HBV-RT/HBsAg gene-overlap, they can have an impact on HBsAg-detection and quantification...
  6. pmc HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors
    Valeria Cento
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata, Rome, Italy
    PLoS ONE 7:e39652. 2012
    ..Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed whether specific HCV-genotypes are differently prone to develop resistance to linear and macrocyclic protease-inhibitors (PIs)...